Investors Offered Lead Role in Beta Bionics Securities Lawsuit

Rosen Law Firm, a global investor rights law firm, is seeking lead plaintiffs for a securities fraud lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX). The firm reminds purchasers of the company's common stock between July 30, 2025, and February 24, 2026, inclusive, of an important lead plaintiff deadline of November 3, 2026.

The lawsuit alleges that Beta Bionics made materially false and misleading statements regarding its automated insulin delivery system, the "iLet Bionic Pancreas." According to the complaint, the company downplayed serious issues raised by the U.S. Food and Drug Administration (FDA) concerning the device's malfunctioning and its tendency to administer dangerously high insulin doses, leading to hypoglycemic events.

Rosen Law Firm claims that thousands of adverse event reports were filed with the FDA, including hundreds of life-threatening incidents. The firm asserts that Beta Bionics failed to implement meaningful corrective actions in response to the FDA's findings and concerns. When the true nature of these issues became public, investors allegedly suffered damages.

Investors who purchased Beta Bionics stock during the specified class period and wish to serve as lead plaintiff are encouraged to contact Rosen Law Firm by the November 3, 2026 deadline. The firm emphasizes the importance of selecting experienced counsel for such cases.